Introduction
The development of neoplasia is associated with alterations in signal transduction pathways that regulate cell proliferation, survival and invasiveness (Hanahan and Weinberg, 2000) . The members of the Rho family of small GTPases act as molecular switches that influence a wide range of cellular processes (Ridley, 2001; Jaffe and Hall, 2005) . Rho activity is frequently increased in human tumors, but as activating mutations in Rho protein genes are rare, the regulators of Rho GTPases may be targeted during oncogenesis (Gomez del Pulgar et al., 2005) . Rho proteins transmit signals in the active, GTP-bound state, which is positively controlled by guanine nucleotide exchange factors that catalyse the exchange of bound GDP for GTP and negatively controlled by Rho GTPase-activating proteins (GAPs) that stimulate GTP hydrolysis (Van Aelst and D'SouzaSchorey, 1997) . Decreased GAP activity could result in sustained Rho signaling that facilitates the growth and metastasis of tumor cells.
The human RhoGAPs are a diverse family of proteins that share a conserved, 150-200 amino acid GAP domain that contains the catalytic activity (Bernards, 2003; Moon and Zheng, 2003) . One subgroup of the human RhoGAPs includes DLC-1 (deleted in liver cancer 1), the human homologue of rat p122RhoGAP (Homma and Emori, 1995; Yuan et al., 1998) , and DLC-2, also known as STARD13 . The DLC-1 and DLC-2 genes encode polypeptides of approximately 1100 amino acids (aa) with a characteristic modular architecture, consisting of an N-terminal sterile a motif (SAM) domain, a serine-rich domain, a RhoGAP domain and a C-terminal steroidogenic acute regulatory protein-related lipid transfer (START) domain (Homma and Emori, 1995; Yuan et al., 1998; Ponting and Aravind, 1999; Ching et al., 2003) . DLC-1 and DLC-2 were shown to have in vitro GAP activity for RhoA and Cdc42 and to influence cell morphology and cytoskeletal organization (Homma and Emori, 1995; Sekimata et al., 1999; Ching et al., 2003; Wong et al., 2003 Wong et al., , 2005 . DLC-1 inhibits the growth, colony-forming ability, tumorigenicity and invasiveness of human liver, breast, ovarian, nasopharyngeal, esophageal and nonsmall cell lung cancer cells (Ng et al., 2000; Yuan et al., 2003 Yuan et al., , 2004 Zhou et al., 2004; Goodison et al., 2005; Syed et al., 2005; Wong et al., 2005; Seng et al., 2006) , and DLC-2 has been shown to inhibit the ras-induced transformation of rodent cells and the growth of breast and liver cancer cells in culture (Nagaraja and Kandpal, 2004; Leung et al., 2005) .
A third member of the deleted in liver cancer gene family is present in the human genome. The KIAA0189 cDNA clone, isolated from a human myeloid cell line library, was noted to encode a protein similar to p122RhoGAP (Nagase et al., 1996) . The gene encoding KIAA0189 (official gene name, STARD8, for 'START domain protein 8') has been localized to the X chromosome and is distinct from the DLC-1 and DLC-2 genes on 8p22 and 13q13.1, respectively. In this communication, we have characterized additional transcripts of the STARD8 locus that have alternative 5 0 ends and analysed the sequence of the predicted protein product, which we term DLC-3. We also present evidence that DLC-3 expression is altered in some human cancers and that DLC-3 can suppress tumor cell growth.
Results

Analysis of DLC-3 transcripts
The STARD8 gene encoding DLC-3 is closely linked to the androgen receptor (AR), oligophrenin 1 (OPHN1) and ephrin-B1 (EFNB1) genes on chromosome Xq13.1 (Figure 1a ). Database searches identified cDNAs that were nearly identical to the original KIAA0189 sequence throughout most of their lengths but differed at the 5 0 ends. Comparison of the cDNA sequences to the genomic DNA sequence revealed the exon structure of the gene (Figure1b and Table 1 ) and showed that the heterogeneity at the 5 0 ends of the DLC-3 transcripts appears to arise through the use of alternative promoters and exon skipping.
A transcript represented by a cDNA from a human endometrium carcinoma cell line (GenBank CR749411, clone DKFZp686H1668), designated DLC-3a, shares exons 2-14 with KIAA0189, now termed DLC-3b. Nucleotides 1-160 and nt 161-194 of the DLC-3a sequence are present in exons 1A and 1B, respectively, located upstream of the first exon of DLC-3b (exon 1C, nt 1-176 of D80011). A third transcript, DLC-3g, represented by a cDNA from a uterine leiomyosarcoma library (IMAGE 5518429, GenBank BC035587) appears to use the same transcription start site as DLC-3a but lacks exon 3, causing a reading frame shift that would result in premature translation termination after 52 aa. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of normal human liver, prostate and mammary gland RNA using primers in exon 1A and exon 5 indicated that the DLC-3a transcript, and not the DLC-3g isoform, is present in these tissues (Figure 1d ). and neighboring genes encoding the androgen receptor (AR), oligophrenin-1 (OPHN1) and ephrin-B1 (EFNB1). The numbers above the line refer to the sequence coordinates, in megabases. (b) Exon organization of the DLC-3 gene. Boxes represent exons and are numbered to correspond with exons 2-14 of the homologous DLC-1 gene (Durkin et al., 2002) . Arrows indicate the potential transcription start sites upstream of exons 1A and 1C. (c) Schematic representation of the exon sequences present at the 5 0 ends of the three DLC-3 transcripts. The KIAA0189 cDNA sequence is designated as the DLC-3b isoform, and the GenBank accession numbers of the cDNAs corresponding to the DLC-3a and g isoforms are given in parentheses. The locations of the putative ATG translation start codons in the three transcripts and the premature TGA stop codon in the DLC-3g isoform are marked. (d) Amplification of cDNA prepared from normal human liver (L), mammary gland (M) and prostate (P) with DLC-3 primers 1F and 5R2. The major RT-PCR product is a 343 bp band containing exon 3 sequences, and not a 261 bp band missing exon 3. The identity of the PCR product was verified by sequencing.
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Features of the DLC-3 protein sequence The DLC-3a transcript has a 3309 bp open reading frame that encodes an 1103-aa polypeptide containing SAM, RhoGAP and START domains (Figures 2 and  3a) . The DLC-3a amino acid sequence is 44% identical to DLC-1 and 52% identical to DLC-2, with the greatest similarity in the RhoGAP domains. The DLC-3 RhoGAP domain contains the conserved 'arginine finger' (Arg688) essential for the catalytic activity of RhoGAPs (Moon and Zheng, 2003) and also has two residues (Lys725 and Arg729) equivalent to ones found to be important for the activity of DLC-1 and DLC-2 (Sekimata et al., 1999; Leung et al., 2005) . Translation initiation at the first ATG codon of the longest open reading frame of the DLC-3b transcript (nt 338-340 of D80011) would yield a 1023-residue protein lacking the SAM domain. The two DLC-3 isoforms are also present in rodents; a 4.4 kb mouse cDNA (AK133927) encodes a 1019-aa protein that is 87% identical to the DLC-3b isoform, and there are mouse expressed sequence tags with 5 0 ends similar to the a form (e.g., GenBank CJ163700).
The serine-rich region between the SAM and Rho-GAP domains has the least sequence similarity among the DLC family members, but there are several conserved stretches that could correspond to sites with biological functions. One of the conserved sequence elements (LDDILQHV, residues 388-395 in DLC-3a) is similar to the consensus LD motif (LDXLLXXL) found in paxillin and other signaling proteins, which mediates the binding of paxillin to vinculin and focal adhesion kinase (Brown et al., 1998) . Downstream of this motif in human DLC-3 is an E80 amino acid insertion enriched in proline, alanine and glutamine residues, which has relatively low homology with the mouse sequence and is missing from chicken, frog, fish and marsupial DLC-3 sequences (not shown). A search for sequence patterns in the serine-rich domain using the Eukaryotic Linear Motif server (http://elm.eu.org) revealed the presence of a number of putative serine and threonine phosphorylation sites, and there are also several prolinerich stretches that could interact with proline recognition motifs such as the SH3 (src homology 3) domain present in many signaling proteins (Li, 2005) (not shown).
Phylogeny of the DLC family genes
In addition to the similarities at the protein level, the exon organizations of the DLC family genes are highly conserved ( Table 1 ), suggesting that the three genes have a common ancestor. The duplications apparently involved an extended region of genomic DNA, as some genes linked to the DLC-3 gene at Xq13 have paralogues linked to the DLC-2 locus on chromosome 13q13 and to the DLC-1 locus on chromosome 8p22 ( Figure 3b ). Sequence comparisons indicate that the genes on 8p (DLC1, SLC7A2 and MTMR7) are more closely related to their paralogues on 13q (DLC2, SLC7A1 and MTMR6) than to those on Xq (DLC3, SLC7A3 and MTMR8). It therefore appears that an initial duplication event yielded the Xq block and an 8p/ 13q precursor that subsequently underwent another round of duplication.
Expression of DLC-3 mRNA in human tissues
The expression pattern of the DLC-3 mRNA in human tissues was examined by Northern blot hybridization ( Figure 4a ). The 5 kb DLC-3 transcript had a broad tissue distribution, with the highest levels in kidney, lung and placenta, similar to earlier results for KIAA0189 (Nagase et al., 1996) . The localization of DLC-3 mRNA was compared to that of DLC-1 and DLC-2 by RT-PCR ( Figure 4b ). The transcripts for all three DLC family members were detected in solid tissues, but the levels were low in peripheral blood lymphocytes. Exons are numbered to correspond to the numbers of the equivalent exons of the DLC-1 gene. b The position of the exon in the cDNA sequence was obtained from GenBank BC035587 for exons 1A and 1B and from GenBank D80011 for exons 1C and 2-14.
c The position of the exon in the genomic DNA sequence was obtained from GenBank AL732324 for exons 1A and 1B and from GenBank AL360076 for exons 1C and 2-14. d The sizes refer to the length of the open reading frame in the sequence of the final exon.
Expression of DLC-3 in human cancers
Northern blot hybridization showed that DLC-3 mRNA levels were low in most of the human breast, prostate and ovarian cancer lines tested, but the mRNA was more abundant in DU-145 prostate cancer, Hoc8 ovarian cancer, and MDA-MB-468 and MDA-MB-436 breast carcinoma cells ( Figure 5 ). In liver cancer cell lines, no DLC-3 transcript was detected in five out of 16 lines assayed by RT-PCR. DLC-3 expression in primary tumors from different tissues was analysed using a Cancer Profiling Array (Figure 6a ). Relative to the adjacent normal tissue, DLC-3 mRNA levels were significantly downregulated in a high percentage of kidney, lung, uterine, ovarian and breast cancers. Owing to the low number of prostate cancer cases in this set, DLC-3 expression was examined in larger group of prostate neoplasms, using real-time RT-PCR to quantitate the transcript levels. In 60% of primary prostate carcinomas, DLC-3 expression was downregulated relative to normal prostate tissue. DLC-3 expression was not significantly altered in benign prostate hyperplasias ( Figure 6b ).
Effect of DLC-3a expression on tumor cell growth
The ability of DLC-1 and DLC-2 to inhibit cell proliferation led us to examine whether DLC-3 possessed similar activity. Human tumor cell lines with low levels of the endogenous DLC-3 transcript were transfected with an expression vector encoding the complete open reading frame of the DLC-3a isoform. Overexpression of DLC-3a inhibited cell proliferation in MCF-7 breast cancer cells and in 22Rv1 prostate cancer cells when compared to cells transfected with the control vector ( Figure 7 ). DLC-3a expression also reduced colony formation in MCF-7 and 22Rv1 cells by 67 and 65%, respectively. The effect of DLC-3a expression on anchorage-independent growth was tested in 22Rv1 cells and in the MDA-MB-361 breast cancer cell line, in which DLC-3 mRNA levels are also low (not shown). DLC-3a expression decreased the number of colonies in soft agar by 49% in 22Rv1 cells and by 71% in MDA-MB-361 cells.
Discussion
DLC-1 and DLC-2 are regulators of Rho GTPase activity that influence the proliferation, cytoskeletal organization and motility of cultured cells. The DLC family proteins also have important roles in normal development, as null alleles of the mouse DLC-1 gene (Durkin et al., 2005) and the single Drosophila DLC-1-like gene (Denholm et al., 2005) result in defective morphogenesis and embryonic lethality. In this report, we present evidence that DLC-3, a third member of the deleted in liver cancer family, may be involved in regulating cell growth. The three DLC genes have an overlapping expression pattern in adult tissues but do not appear to be redundant, as the severe phenotype of DLC-1 À/À mice suggests that DLC-2 and -3 were unable to compensate for the loss of DLC-1 during embryogenesis (Durkin et al., 2005) . There may be variations in the temporal or cell-type expression of the DLC-1, -2 and -3 genes, or the amino acid sequence differences DLC3  MPLLDVFWSCFRKVKCFPLLQVKKNAEAEAKRACEWLQATGFPQYVQLFEEGSFPLDIGS  60  DLC1  --------------MCRKKPDTMILTQIEAKEACDWLRATGFPQYAQLYEDFLFPIDISL  46  DLC2  DQTTRRSPYRMSRILARHQLVTKIQQEIEAKEACDWLRAAGFPQYAQLYEDSQFPINIVA  90   DLC3  VKKHNGFLDEDSLGALCRRLMTLNNCASMKLEVHFQSKQNEDSEEEEQCTISSHWAFQQE  120  DLC1  VKREHDFLDRDAIEALCRRLNTLNKCAVMKLEISPHRKRSDDSDEDEPCAISGKWTFQRD  106  DLC2 VKNDHDFLEKDLVEPLCRRLNTLNKCASMKLDVNFQRKKGDDSDEEDLC-ISNKWTFQRT 149 - Figure 2 Alignment of the amino acid sequences of the three human deleted in liver cancer family members. The amino acid sequences of DLC-3a (residues 1-1103 of UniProt entry Q68DG7, the translation of nt 116-3427 of CR749411), DLC-1 (residues 1-1091 of UniProt Q96QB1) and DLC-2 (residues 30-1113 of the a isoform, UniProt Q9Y3M8) were aligned using the ClustalW 1.81 program, and the alignment in the serine-rich domain was then edited manually. The amino acid numbering is on the right, and dashes indicated gaps introduced to maximize the sequence identity. Amino acids that are identical in at least two of the three sequences are highlighted in gray. The three amino acids in the RhoGAP domains important for biological activity are highlighted in black.
DLC3 SKCWSPMGSSDLLAPPSP----------------------GLPATSSCESVLTELSATSL
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DLC-3 and cancer ME Durkin et al between the three proteins may be sufficient to alter their interaction repertoires and lead to functional specialization. The DLC-3 gene appears to have two promoters that yield transcripts with alternative 5 0 ends. The sequences flanking both of the putative transcription starts sites upstream of exons 1A and 1C have a high GC content, typical of the CpG islands associated with promoter regions. The protein products of the DLC-3 a and b transcripts are predicted to differ by the presence or absence, respectively, of the N-terminal SAM domain. Similar variants have been reported for the human DLC-2 gene, the DLC-2a (plus SAM) and DLC-2g (minus SAM) forms . SAM domains are approximately 70-aa motifs that mediate proteinprotein interactions (Qiao and Bowie, 2005) , and the two DLC-3 isoforms could have different biological properties, as was shown for variants of diacylglycerol kinase Z with or without a C-terminal SAM domain (Murakami et al., 2003) .
The high degree of similarity between the GAP domain of DLC-3 and those of DLC-1 and DLC-2 suggests that DLC-3 may also act as a GAP with comparable substrate specificity. The RhoGAP domains of DLC-1 and DLC-2 were found to be essential for their effects on cytoskeletal organization and cell proliferation (Sekimata et al., 1999; Ching et al., 2003; Leung et al., 2005; Wong et al., 2005) . The other domains of the DLC family polypeptides may regulate the activity of the GAP domain through intra-or intermolecular interactions or mediate the subcellular localization of the protein. The START domain is a potential lipid-binding domain (Ponting and Aravind, 1999; Alpy and Tomasetto, 2005) and could be involved in membrane targeting of the protein or in conferring lipid-regulated conformational changes, like the lipidbinding domains of other RhoGAPs (Bernards and Settleman, 2004) .
The largest domain in the DLC-3 protein is the 530-aa serine-rich domain, encoded primarily by a single large (DLC2) and STARD8 (DLC3) loci. The gene order is based on the DNA sequence maps of the three chromosomes; the distances are not drawn to scale. The paralogous blocks on Xq and 13q were previously identified (McLysaght et al., 2002 ; available online at http:// wolfe.gen.tcd.ie/dup). Paralogous genes on 8p were identified by visual inspection of the human genome map at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/mapview/). To the left is a phylogenetic tree of the Xq, 13q and 8p chromosomal regions, based on the degree of similarity between the DLC, MTMR (myotubularin) and SLC7 (amino acid transporter) family members, as calculated by the Hovergen database of homologous vertebrate genes at the ExPASY Proteomics server (ca.expasy.org).
DLC-3 and cancer ME Durkin et al exon, as in the DLC-1 and -2 genes. This region is predicted to contain a number of potential serine/ threonine phosphorylation sites, and recently Ser322 of rat DLC-1/p122RhoGAP was found to be phosphorylated in adipocytes after insulin treatment (Hers et al., 2006) . Both serine/threonine and tyrosine phosphorylation have been found to regulate the activity of other RhoGAP proteins (Moon and Zheng, 2003; Bernards and Settleman, 2004) . The serine-rich region of DLC-3 also has potential motifs for binding to prolinerecognition domains, and thus this domain may possess multiple sites for interacting with other proteins to form signaling complexes. The gene-encoding DLC-3 is flanked by several wellcharacterized genes that are mutated in human genetic disorders, including androgen insensitivity (AR, Avila et al., 2001) , one form of X-linked mental retardation (OPHN1, Billuart et al., 1998) , and the skeletal disorder craniofrontonasal syndrome (EFNB1, Wieland et al., 2004) . A female with craniofrontonasal syndrome was recently found to have a deletion of EFNB1 that also included part of STARD8/DLC3 (Twigg et al., 2006) . As STARD8 is subject to X-inactivation (Carrel and Willard, 2005) , further phenotypic analyses of patients with deletions extending to STARD8 could reveal additional clinical features resulting from mosaic DLC-3 deficiency.
DLC-3 mRNA levels were low or undetectable in most of the human breast, ovarian and prostate cancer cell lines tested and were also decreased in the majority of primary tumors from these tissues. Our results are consistent with microarray gene expression profiling data showing downregulation of DLC-3 expression in human prostate tumors (cited in Alpy and Tomasetto, 2005) and in transgene-induced mouse mammary tumors (Thakur et al., 2005) . Transcription of the DLC-3 gene could be repressed by epigenetic mechanisms such as promoter DNA hypermethylation and histone hypoacetylation, as has been found for DLC-1 P-labeled DLC-3 cDNA probe (5F/5R1). The same blot was re-hybridized to a ribosomal protein L19 probe (RpL19) as a control for loading. (b) Aliquots of cDNA from human brain, heart, kidney, liver, peripheral blood lymphocytes (PBL) and spleen RNA were amplified with primers specific for human DLC-1, DLC-2 and DLC-3 (7F/9R). Control amplifications were performed with primers for human GAPDH. in prostate carcinomas (Guan et al., 2006) . Reduced DLC-3 mRNA levels could also result from genomic DNA losses. Loss of heterozygosity studies have suggested the presence of one or more tumor suppressor genes on the X chromosome (reviewed in Spatz et al., 2004) , and the DLC-3 locus is close to an Xq region commonly lost in ovarian epithelial tumors (Edelson et al., 1998) . Generation of DLC-3-specific antibodies will be needed to determine whether DLC-3 expression in tumors is reduced at the protein level and whether this is correlated with changes in mRNA levels.
Consistent with a potential role for DLC-3 as a tumor suppressor, we found that overexpression of DLC-3a in human breast and prostate cancer cell lines inhibited colony formation and cell proliferation. DLC-3 expression also reduced anchorage-independent growth in soft agar, an in vitro measure of tumorigenicity. Overexpression of DLC-3 could decrease the global levels of active, GTP-bound Rho proteins or inhibit the GDP-GTP cycling process, interfering with signals necessary for promoting cell growth and survival. A better understanding of the role of DLC-3 in signal transduction will require additional characterization of the polypeptide, to identify its interaction partners and the upstream factors that regulate its activity. In a recent large-scale mutational analysis of human cancers, missense mutations in STARD8 were found in human breast tumors (Sjo¨blom et al., 2006) , providing further evidence that alterations in DLC-3 may affect cellular functions.
Materials and methods
RNA preparation and analysis
Human cancer cell lines were obtained and cultured as described previously (Guan et al., 2006; Ullmannova and Popescu, 2006) , and total RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) or the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA from normal human liver, mammary gland and prostate were purchased from Stratagene (La Jolla, CA, USA) or Clontech (Mountain View, CA, USA). First strand cDNA was transcribed from total RNA using the Thermoscript RT-PCR kit (Invitrogen) or the cDNA Archive kit (Applied Biosystems, Foster City, CA, USA). The six tissue Multiple Choice Human First Strand cDNA panel (CH1101) was purchased from OriGene Technologies (Rockville, MD, USA). The sequences of the primers used for PCR amplification of cDNAs are listed in Table 2 . For Northern-blot analysis, aliquots of total RNA from human cancer cell lines were denatured, fractionated by agarose gel electrophoresis and transferred to nylon membranes as described (Yuan et al., 2003) . A 12-tissue human poly (A þ ) RNA Northern blot was purchased from OriGene Technologies. DLC-3 cDNA probes were prepared by RT-PCR using primers 5F/5R1 or 7F/11R and labeled with [ 32 P]dCTP by oligolabeling. Northern blots were hybridized to the probes and washed as described previously (Yuan et al., 2003) . DLC-3 mRNA levels were measured in three normal prostate tissues, 10 cases of benign prostate hyperplasia (BPH), and 10 prostate carcinomas (PCa), and the expression was normalized to that of GAPDH. In parentheses is the number of samples in which the relative DLC-3 expression was less than onehalf of the average normal level, indicated by the horizontal line.
Expression of DLC-3 in human tumors
The Cancer Profiling Array I, which contains normalized cDNAs from matched pairs of tumor and normal tissues from 241 individuals with 19 tumor types, was purchased from BD Biosciences (San Jose, CA, USA). Hybridization of the filter to 32 P-labeled probes and analysis of the data were performed as described previously (Ullmannova and Popescu, 2006) .
DLC-3 expression in prostate tumor samples
Tissue specimens from three normal prostates, 10 prostate carcinomas and 10 cases of benign prostate hyperplasia were obtained from the University Hospital of Heraklion, Crete, Greece, and total RNA was extracted from the tissue samples and transcribed into cDNA as described earlier (Guan et al., 2006) . Gene expression was assessed by quantitative real-time RT-PCR using the ABI PRISM 7900 Sequence Detection System instrument and software (Applied Biosystems) with QuantiTect SYBR Green PCR reagents (Qiagen). Primers for human DLC-3/STARD8 (catalogue # PPH10566A) were purchased from SuperArray (Frederick, MD, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous reference gene for normalizing variance in the quality of RNA and the amount of input cDNA, using primers described by Song et al. (2006) . After an initial denaturation step at 951C for 15 min, 40 cycles of amplification (941C, 15 s; 551C, 30 s; 551C, 30 s) were performed. Amplification was Primer 1F sequence is from BC035587, and the other sequences are from D80011.
DLC-3 and cancer ME Durkin et al immediately followed by a melt program to validate the specificity of the PCR products. The 2 ÀDDCT method was used to calculate the relative fold difference in DLC-3 expression compared to the average ratio of normal tissues. A twofold reduction was considered significant.
DLC-3a expression vector construction
First strand cDNA synthesized from Hoc8 ovarian carcinoma RNA was amplified by PCR using the DLC-3 1F/5R3 primers, and the product was digested with XhoI. The 0.55 kb fragment was gel-purified, cloned into the EcoRV-and XhoI-cut pBluescript SK vector (Stratagene), and sequenced to verify its identity. The plasmid DNA was digested with XhoI and SalI and ligated to a 3.1 kb XhoI/SalI fragment (nt 683-3810 of GenBank BC035587) from the DLC-3g cDNA clone (IMAGE 5518429, purchased from the American Type Culture Collection). The resulting plasmid contained a 3.6 kb insert with the complete open reading frame of the DLC-3a cDNA. The insert was excised as an EcoI/SalI fragment and cloned into EcoRIand XhoI-cut pcDNA3.1 (Invitrogen), to generate a plasmid that expressed the DLC-3a isoform under the control of the cytomegalovirus promoter.
Analysis of DLC-3-transfected cells
Cells at 70% confluency were transfected with the DLC3a/ pcDNA3.1 plasmid or with the pcDNA3.1 vector with no insert, using GeneJuice Transfection Reagent (Novagen, Madison, WI, USA) for 2 days. To determine the effect of DLC-3a expression on cell growth, 2 Â 10 2 , 2 Â 10 3 and 2 Â 10 4 of MCF-7 and 22Rv1 cells were seeded in triplicate on a 96-well plate and incubated for 10 days. Cell proliferation was measured every other day by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction assay (Promega, Madison, WI, USA). For colony formation assays, cells were grown for 2 days in medium containing 250 mg/ml G418 sulfate (Geneticin, Invitrogen), and then 1 Â 10 6 cells were seeded in a 100 mm dish with G418-supplemented medium for 2 weeks. Colonies were stained with 0.5% crystal violet after fixation with 70% ethanol. To test for anchorage-independent growth, transfected cells cultured in G418 for 2 days were seeded on soft agar plates according to the manufacturer's protocol (Chemicon, Temecula, CA, USA) and cultured in the appropriate medium for 4 weeks. Colonies were then stained overnight with Cell Staining Solution (Chemicon) and counted.
